title: Molecular alterations in glioblastoma: potential targets for immunotherapy.
abstract: Glioblastoma is the most common and deadly brain tumor, possibly arising from genetic and epigenetic alterations in normal astroglial cells. Multiple cytogenetic, chromosomal, and genetic alterations have been identified in glioblastoma, with distinct expression of antigens (Ags) and biomarkers that may alter therapeutic potential of this aggressive cancer. Current therapy consists of surgical resection, followed by radiation therapy and chemotherapy. In spite of these treatments, the prognosis for glioblastoma patients is poor. Although recent studies have focused on the development of novel immunotherapeutics against glioblastoma, little is known about glioblastoma-specific immune responses. A better understanding of the molecular interactions among glioblastoma tumors, host immune cells, and the tumor microenvironment may give rise to novel integrated approaches for the simultaneous control of tumor escape pathways and the activation of antitumor immune responses. This review provides a detailed overview concerning genetic alterations in glioblastoma, their effects on Ag and biomarker expression, and the future design of chemoimmunotherapeutics against glioblastoma.
authors.affiliation: Department of Microbiology and Immunology, Medical University of South Carolina, Charleston, South Carolina, USA.
authors.forename: Azizul
authors.initials: A
authors.lastname: Haque
authors.forename: Naren L
authors.initials: NL
authors.lastname: Banik
authors.forename: Swapan K
authors.initials: SK
authors.lastname: Ray
mesh_terms: D000951:Antigens, Neoplasm / Q000276:immunology; D014408:Biomarkers, Tumor / Q000378:metabolism; D016207:Cytokines / Q000378:metabolism; D005909:Glioblastoma / Q000235:genetics* / Q000276:immunology / Q000628:therapy*; D006801:Humans; D007167:Immunotherapy; D058990:Molecular Targeted Therapy
chemical_list: D000951:Antigens, Neoplasm; D014408:Biomarkers, Tumor; D016207:Cytokines